Growth Hormone and Health Policy

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2010 Apr 30

PMID 20427500

Citations 9

Authors

Leona Cuttler

J B Silvers

Affiliations

Soon will be listed here.

Abstract

GH treatment for short children is representative of many frontline issues in health care policy. In this paper, we highlight key policy issues exemplified by GH, focusing on pharmaceutical innovation, insurance coverage and pricing, and physician decisions, and we discuss their implications for endocrinology and GH use.

Citing Articles

Effectiveness and Safety of Combination Therapy with Herbal Medicine and Growth Hormone Compared to Growth Hormone Monotherapy for Short Stature Children: A Systematic Review and Meta-Analysis.

Shim S, Ahn H, Lee H, Lee J, Lee H Evid Based Complement Alternat Med. 2022; 2022:5725258.

PMID: 35982997 PMC: 9381207. DOI: 10.1155/2022/5725258.

Effects of Early Initiation of Growth Hormone Therapy on Different Auxological Parameters in Growth Hormone Deficient Children: Experience from an Indian Tertiary Care Center.

Kochar I, Ramachandran S, Sethi A Indian J Endocrinol Metab. 2021; 25(1):54-58.

PMID: 34386395 PMC: 8323637. DOI: 10.4103/ijem.IJEM_739_20.

Shared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.

Acerini C, Segal D, Criseno S, Takasawa K, Nedjatian N, Rohrich S Front Endocrinol (Lausanne). 2018; 9:688.

PMID: 30524377 PMC: 6262035. DOI: 10.3389/fendo.2018.00688.

Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit.

Sotos J, Tokar N Int J Pediatr Endocrinol. 2014; 2014(1):15.

PMID: 25075207 PMC: 4114101. DOI: 10.1186/1687-9856-2014-15.

Assessing the quality of life of health-referred children and adolescents with short stature: development and psychometric testing of the QoLISSY instrument.

Bullinger M, Quitmann J, Power M, Herdman M, Mimoun E, DeBusk K Health Qual Life Outcomes. 2013; 11:76.

PMID: 23648112 PMC: 3666886. DOI: 10.1186/1477-7525-11-76.

References

Daniel Mullins C, DeVries A, Hsu V, Meng F, Palumbo F . Variability and growth in spending for outpatient specialty pharmaceuticals. Health Aff (Millwood). 2005; 24(4):1117-27. DOI: 10.1377/hlthaff.24.4.1117. View

Chernew M, Juster I, Shah M, Wegh A, Rosenberg S, Rosen A . Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010; 29(3):530-6. DOI: 10.1377/hlthaff.2009.0119. View

Dudzinski D, Kesselheim A . Scientific and legal viability of follow-on protein drugs. N Engl J Med. 2008; 358(8):843-9. DOI: 10.1056/NEJMhle0706973. View

Cuttler L, Kenney G . Update on the State Children's Health Insurance Program. Arch Pediatr Adolesc Med. 2009; 163(2):103-7. DOI: 10.1001/archpediatrics.2008.558. View

Rosenbloom A . Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature?. Lancet. 2006; 368(9535):612-6. DOI: 10.1016/S0140-6736(06)69205-2. View

Bundorf M, Royalty A, Baker L . Health care cost growth among the privately insured. Health Aff (Millwood). 2009; 28(5):1294-304. DOI: 10.1377/hlthaff.28.5.1294. View

Ross J, Lackner J, Lurie P, Gross C, Wolfe S, Krumholz H . Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA. 2007; 297(11):1216-23. DOI: 10.1001/jama.297.11.1216. View

Sirovich B, Gallagher P, Wennberg D, Fisher E . Discretionary decision making by primary care physicians and the cost of U.S. Health care. Health Aff (Millwood). 2008; 27(3):813-23. PMC: 2438037. DOI: 10.1377/hlthaff.27.3.813. View

Wyatt D, Mark D, Slyper A . Survey of growth hormone treatment practices by 251 pediatric endocrinologists. J Clin Endocrinol Metab. 1995; 80(11):3292-7. DOI: 10.1210/jcem.80.11.7593441. View

10.

Finkelstein B, Silvers J, Marrero U, Neuhauser D, Cuttler L . Insurance coverage, physician recommendations, and access to emerging treatments: growth hormone therapy for childhood short stature. JAMA. 1998; 279(9):663-8. DOI: 10.1001/jama.279.9.663. View

11.

Glasbrenner K . Technology spurt resolves growth hormone problem, ends shortage. JAMA. 1986; 255(5):581-4, 587. DOI: 10.1001/jama.255.5.581. View

12.

Sox H, Greenfield S . Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009; 151(3):203-5. DOI: 10.7326/0003-4819-151-3-200908040-00125. View

13.

Chernew M, Rosen A, Fendrick A . Value-based insurance design. Health Aff (Millwood). 2007; 26(2):w195-203. DOI: 10.1377/hlthaff.26.2.w195. View

14.

Brand R . Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts. State Legis. 2008; 34(8):26-9. View

15.

Wennberg J . Practice variations and health care reform: connecting the dots. Health Aff (Millwood). 2004; Suppl Variation:VAR140-4. DOI: 10.1377/hlthaff.var.140. View

16.

Goldman D, Joyce G, Lawless G, Crown W, Willey V . Benefit design and specialty drug use. Health Aff (Millwood). 2006; 25(5):1319-31. PMC: 6349207. DOI: 10.1377/hlthaff.25.5.1319. View

17.

Golenski J . Specialist discretion for managing specialty pharmaceuticals: the ethics argument for discretion. Am J Manag Care. 2004; 10(8 Suppl):S240-1. View

18.

. Insulin-like growth factor-1 for severe growth failure. Med Lett Drugs Ther. 2007; 49(1261):43-4. View

19.

Brewer G . Drug development for orphan diseases in the context of personalized medicine. Transl Res. 2009; 154(6):314-22. DOI: 10.1016/j.trsl.2009.03.008. View

20.

Cuttler L, Marinova D, Mercer M, Connors A, Meehan R, Silvers J . Patient, physician, and consumer drivers: referrals for short stature and access to specialty drugs. Med Care. 2009; 47(8):858-65. DOI: 10.1097/MLR.0b013e31819e1f04. View